IMHO The Street Still Does Not Get IT. 6 years of lurking going back to the YMB days when the Orange Book updates were our dose of monthly torment. A warm thank you to JL, AVI, Vubru, TTE, HD and many others for helping me keep the faith while staring at red every morning.
Hopefully somewhere in the FDA somebody has realized that the Adcom red wedding cost thousands of lives and untold morbidity. For what reason? Unlike so many other drugs, Vascepa has the safety profile of spring water. BB keep it up!
As JL has noted the implications of what Amarin has created are simply staggering and can be applied far beyond cardiology. From my small specialty I suggest googling the following terms 1) Macular degeneration and cholesterol. 2) Diabetic macular edema and triglycerides. These are the two leading causes of blindness in the western world. The science clearly points to Vascepa being efficacious for both of these diseases. I want to find out.
We have only scratched the surface of what pan-suppression of inflammation can do. Vascepa will have utility for autoimmune diseases, vascular conditions, neurodegenerative disorders, and many others. The years to come will see studies ranging all across medicine. With no side effects, IRBs will be easy to obtain and studies will only be limited by funding.
I have to assume that big pharma may be realizing this now. Lovaza's market is now entirely Amarin's, and a combo drug will reboot their statin patents.
There are many on this board who can at least estimate what this is all worth. I think I am safe to say the stock is still currently very inexpensive and a PPS of 50 is not unreasonable.
See everyone again when we are there.